

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

RECKITT BENCKISER
PHARMACEUTICALS INC., RB
PHARMACEUTICALS LIMITED, and
MONOSOL RX, LLC,

Plaintiffs,

v.

DR. REDDY'S LABORATORIES S.A., and
DR. REDDY'S LABORATORIES, INC.,

Defendants.

Civil Action No. 14-1451-RGA

RECKITT BENCKISER
PHARMACEUTICALS INC., RB
PHARMACEUTICALS LIMITED, and
MONOSOL RX, LLC,

Plaintiffs,

v.

PAR PHARMACEUTICAL, INC. and
INTELGENX TECHNOLOGIES CORP.,

Defendants.

Civil Action No. 14-1573-RGA

RECKITT BENCKISER
PHARMACEUTICALS INC., RB
PHARMACEUTICALS LIMITED, and
MONOSOL RX, LLC,

Plaintiffs,

v.

WATSON LABORATORIES, INC. and
ACTAVIS LABORATORIES UT, INC.,

Defendants.

Civil Action No. 14-1574-RGA

TRIAL OPINION

Mary W. Bourke, Dana K. Severance, Daniel M. Attaway, WOMBLE CARLYLE
SANDRIDGE & RICE, LLP, Wilmington, DE.

Par v. MonoSol
IPR2017-001557
MONOSOL EX. 2001

Attorneys for Plaintiffs.

Daniel A. Ladow, James M. Bollinger, Timothy P. Heaton, J. Magnus Essunger, TROUTMAN SANDERS LLP, New York, NY; Charanjit Brahma, TROUTMAN SANDERS LLP, San Francisco, CA; Robert E. Browne, Jr., TROUTMAN SANDERS LLP, Chicago, IL; Puja Patel Lea, TROUTMAN SANDERS LLP, Atlanta, GA; Jeffrey B. Elikan, Jeffrey Lerner, Erica N. Andersen, Ashley M. Kwon, COVINGTON & BURLING LLP, Washington, DC

Attorneys for Plaintiffs Reckitt Benckiser Pharmaceuticals Inc. and RB Pharmaceuticals Limited

James F. Hibey, Timothy C. Bickham, STEPTOE & JOHNSON LLP, Washington, DC; David L. Hecht, Cassandra A. Adams, STEPTOE & JOHNSON LLP, New York, NY

Attorneys for Plaintiff MonoSol Rx, LLC

Richard D. Kirk, Stephen B. Brauerman, Sara E. Bussiere, BAYARD, P.A., Wilmington, DE; Elaine H. Blais, Robert Frederickson, III, Molly R. Grammel, Alexandra Lu, Kathryn, Kosinski, GOODWIN PROCTER LLP, Boston, MA; Ira J. Levy, Robert V. Cerwinsky, GOODWIN PROCTER LLP, New York, NY; John Coy Stull, GOODWIN PROCTOR LLP, Washington, DC

Attorneys for Defendants Dr. Reddy's Laboratories S.A. and Dr. Reddy's Laboratories, Inc.

Steven J. Fineman, Katharine L. Mowery, RICHARDS, LAYTON & FINGER, P.A., Wilmington, DE; Daniel G. Brown, LATHAM & WATKINS LLP, New York, NY; Jennifer Koh, B. Thomas Watson, LATHAM & WATKINS LLP, San Diego, CA; Emily C. Melvin, Brenda L. Danek, LATHAM & WATKINS LLP, Chicago, IL; Terry Kearney, Michelle Woodhouse, Jie Wang, LATHAM & WATKINS LLP, Menlo Park, CA; B. Thomas Watson, LATHAM & WATKINS LLP, San Diego, CA.

Attorneys for Defendants Par Pharmaceutical, Inc. and IntelGenx Technologies Corp.

John C. Phillips, Jr., Megan C. Haney, PHILLIPS, GOLDMAN & SPENCE, P.A., Wilmington, DE; George C. Lombardi, Michael K. Nutter, WINSTON & STRAWN LLP, Chicago, IL; Stephen Smerek, David P. Dalke, Jason C. Hamilton, WINSTON & STRAWN LLP, Los Angeles, CA.

Attorneys for Defendants Watson Laboratories, Inc. and Actavis Laboratories UT, Inc.

August 31, 2017



ANDREWS, U.S. DISTRICT JUDGE:

Plaintiffs Reckitt Benckiser Pharmaceuticals, Inc.,¹ RB Pharmaceuticals Limited,² and MonoSol Rx, LLC (collectively, “Plaintiffs”) bring this suit against Defendants Dr. Reddy’s Laboratories S.A. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”),³ Defendant Watson Laboratories, Inc.⁴ (“Watson”), and Defendants Par Pharmaceutical, Inc. and IntelGenx Technologies Corporation (collectively, “Par”). This opinion addresses allegations of infringement and invalidity with respect to U.S. Patent Nos. 8,603,514 (“the ’514 patent”) and 8,900,497 (“the ’497 patent”).

The Court held a four-day bench trial relating to these patents. (D.I. 299; D.I. 300; D.I. 301; D.I. 302).⁵ The parties filed proposed findings of fact (D.I. 275), post-trial briefing with respect to infringement (D.I. 279; D.I. 285; C.A. No. 14-1574, D.I. 184; C.A. No. 14-1573, D.I. 203; D.I. 295), and post-trial briefing with respect to invalidity (D.I. 278; D.I. 288; D.I. 293). I have also considered letters submitted regarding *Medicines Co. v. Mylan, Inc.*, 853 F.3d 1296 (Fed. Cir. 2017). (D.I. 309; D.I. 310). Having considered the documentary evidence and testimony, I make the following findings of fact and conclusions of law pursuant to Federal Rule of Civil Procedure 52(a).

¹ Citations to “D.I. ___” are to the docket in C.A. No. 14-1451 unless otherwise noted. Plaintiff Reckitt Benckiser Pharmaceuticals, Inc. is now known as Indivior Inc. (D.I. 228-2, Admitted Fact No. 2).

² Plaintiff Reckitt Benckiser Pharmaceuticals Limited is now known as Indivior UK Limited. (D.I. 228-2, Admitted Fact No. 4).

³ DRL was substituted as a party in place of Teva Pharmaceuticals USA, Inc. following Teva’s transfer of ownership of ANDA Nos. 205299 and 205806 to DRL. (D.I. 228-2, Admitted Fact No. 12 at n.2).

⁴ Defendant Watson Laboratories, Inc. is now known as Actavis Laboratories UT, Inc. (D.I. 228-2, Admitted Fact No. 6).

⁵ Although the official transcript is filed in four parts (D.I. 299; D.I. 300; D.I. 301; D.I. 302), citations to the transcript herein are generally cited as “Tr.”

I. BACKGROUND

Plaintiff Reckitt Benckiser Pharmaceuticals, Inc. is the holder of approved New Drug Application No. 22-410 for Suboxone® sublingual film, which is indicated for maintenance treatment of opioid dependence. (D.I. 228-2, Admitted Fact Nos. 13–14, 20). The active ingredients of Suboxone® sublingual film are buprenorphine hydrochloride and naloxone hydrochloride. (D.I. 228-2, Admitted Fact No. 15). Suboxone® sublingual film is available in four dosage strengths (buprenorphine hydrochloride/naloxone hydrochloride): 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg. (D.I. 228-2, Admitted Fact Nos. 16–18). Since the approval of NDA No. 22-410, Suboxone® sublingual film has been exclusively manufactured in the United States by Plaintiff MonoSol and exclusively sold in the United States by Plaintiff Reckitt Benckiser Pharmaceuticals, Inc. (D.I. 228-2, Admitted Fact No. 19).

The '514 patent, entitled “Uniform Films for Rapid Dissolve Dosage Form Incorporating Taste-Masking Compositions,” issued on December 10, 2013. (D.I. 228-2, Admitted Fact No. 21). The '514 patent is listed in the FDA’s Approved Drug Products with Therapeutic Equivalences Evaluations (the “Orange Book”) as covering Suboxone® sublingual film. (D.I. 228-2, Admitted Fact No. 23).

The '497 patent, entitled “Process for Making a Film Having a Substantially Uniform Distribution of Components,” issued on December 2, 2014. (D.I. 228-2, Admitted Fact No. 27). Plaintiff MonoSol owns the '514 and '497 patents and Plaintiff Reckitt Benckiser Pharmaceuticals, Inc. is an exclusive licensee of the '514 and '497 patents. (D.I. 228-2, Admitted Fact Nos. 22, 28).

Plaintiffs are asserting claims 62–65, 69, 71, and 73 of the '514 patent against DRL. (D.I. 228-2, Admitted Fact No. 91; D.I. 279 at 1 n.1). Claim 62 of the '514 patent is an

independent claim. Claims 63, 64, 65, 69, 71, and 73 all depend from claim 62. (D.I. 228-2, Admitted Fact No. 92). The '514 patent was separately tried against Watson and Par. (C.A. No. 13-1674, D.I. 446).

The asserted independent claim of the '514 patent reads as follows.

62. A drug delivery composition comprising:

(i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one active;

wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;

(ii) a particulate active substantially uniformly stationed in the matrix; and

(iii) a taste-masking agent selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof to provide taste-masking of the active;

wherein the particulate active has a particle size of 200 microns or less and said flowable water-soluble or water swellable film-forming matrix is capable of being *dried* without loss of substantial uniformity in the stationing of said particulate active therein; and

wherein the uniformity subsequent to casting and *drying* of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active.

(JTX-2, claim 62) (emphases added).

Plaintiffs are asserting claim 24 of the '497 patent against all Defendants. (D.I. 228-2, Admitted Fact Nos. 30, 64, 95). Claim 24 of the '497 patent depends from claim 1. (D.I. 228-2, Admitted Fact No. 96). Claims 1 and 24 of the '497 patent reads as follows.

1. A process for making a film having a substantially uniform distribution of components, comprising the steps of:

(a) forming a flowable polymer matrix comprising an edible polymer, a solvent and a desired amount of at least one active, said matrix having a substantially uniform distribution of said at least one active;

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.